The pre-op nurse asks whether you use cannabis, and something tightens in your chest. Maybe you took a gummy two nights ago to sleep. Maybe you use it daily for back pain. You picture the surgery getting cancelled, a note landing in your permanent file, a surgeon looking at you differently.

So you say no. Or you say “occasionally,” which is its own kind of no.

That instinct is understandable and it works against you. Nobody asks so they can think less of you. They ask because the answer feeds into your anesthetic dose, your pain plan for the next two days, and the list of things the recovery nurse gets told to watch. So let’s go through what the anesthesia team is fishing for, and where that answer ends up.

The Question Exists Because the Data Changed

In January 2023, ASRA Pain Medicine published the first US consensus guidelines on managing surgical patients who use cannabis (Shah S, et al., Regional Anesthesia & Pain Medicine, 2023). Twenty-one recommendations came out of it, every one agreed on by the whole committee. The American Society of Anesthesiologists looked them over and signed off.

The very first recommendation, and one of the few graded A: screen every surgical patient for cannabis use. Not the ones who look like users. Everyone.

Why the strongest possible grade on a screening question? Because the population shifted underneath clinical practice. SAMHSA’s 2024 survey counted 44.3 million Americans using cannabis in the past month – 15.4% of the country, up from 37 million three years earlier. Surgical populations moved the same way. Researchers at Beth Israel Deaconess went through 210,639 surgery patients and watched the share of cannabis users climb from 4.9% in 2008 to 14.3% by 2020 (Ahrens E, et al., eClinicalMedicine, 2023).

Anesthesiologists are no longer asking an unusual question. They are asking one that applies to roughly one patient in seven.

Legal, Herbal, and Hemp-Derived All Count

Here is where disclosure quietly fails even among patients who intend to be honest.

Someone who buys legal THC gummies online under the hemp rules does not picture themselves as a cannabis user. The product shipped through the mail. It was legal in their state. There was no dispensary, no medical card, nothing that felt clinical. So when the intake form says “marijuana,” they answer no – truthfully, as they understand the question.

The pharmacology disagrees. Delta-9 THC is delta-9 THC. Calling the plant hemp instead of marijuana doesn’t change the molecule, and your liver treats both the same way, producing the same metabolite either way. Standard drug screens cannot distinguish the two sources. The legal category describes the supply chain, not what reaches your receptors.

The same blind spot covers CBD. No psychoactivity, so patients skip it – but CBD is a meaningful inhibitor of several CYP450 enzymes, which is exactly why it matters perioperatively.

Quick tip: Rather than answering the category question, describe the product. “I take a 10 mg hemp gummy most nights” tells the anesthesia team everything. “No, I don’t use marijuana” tells them nothing useful and is, in a technical sense, true.

(A note on timing: US hemp law is mid-rewrite as of September 2026, with a revised federal THC standard pending in December. Whatever the legal status settles into, it will not change the clinical relevance.)

What Changes Once You Tell Them

The Cleveland Clinic ran the largest analysis available on this: 34,521 elective surgery patients, 1,683 of them cannabis users (Ekrami E, et al., Anesthesia & Analgesia, October 2024). Users consumed roughly 30% more opioid in the first 24 hours after surgery and reported higher pain scores. Lead author Elyad Ekrami summarized it bluntly – adults who use cannabis have more postoperative pain, not less.

That surprises people who use cannabis for pain. But it gives your team something to work with: a plan built around multimodal and regional analgesia from the start, rather than chasing pain that is already ahead of you at hour three.

Sedation dosing is the other adjustment. A small Colorado study of endoscopy patients found regular users needed substantially more propofol (Twardowski MA, et al., Journal of Osteopathic Medicine, 2019) – though with only 25 users in the sample, treat that finding as a signal rather than a number. A larger case-control study put the difference at about 76 mg of additional propofol in daily users (Imasogie N, et al., PLoS One, 2021). The Anesthesia Patient Safety Foundation notes the effect is not yet confirmed by well-designed trials, and several orthopedic and cardiac surgery studies found no difference at all.

Translation: the effect appears real in heavy users and inconsistent in light ones. Your anesthesiologist would rather know which one you are before induction than discover it during.

The Edible Problem Nobody Warns You About

Smoking has a rule. ASRA recommends delaying elective surgery at least two hours after cannabis is smoked, drawn from a case-crossover study showing myocardial infarction risk elevated roughly 4.8-fold in the first hour after use (Mittleman MA, et al., Circulation, 2001).

Edibles have no rule. ASRA graded the non-smoked routes “I” – insufficient evidence to recommend any specific duration. That gap is not permission. It is an absence.

Two practical consequences follow. First, an edible taken on the morning of surgery is solid food and violates preoperative fasting requirements, with genuine aspiration risk (Hepner D, Harvard Health, 2020). A gummy isn’t a clear liquid. Swallowing one quietly at 6 a.m. and saying nothing is about the quickest route to a postponed case I can think of.

The other thing is timing, which runs longer than people expect. Peak plasma THC after ingestion arrives at one to two hours, compared with five to ten minutes when smoked. Oral dosing also produces far more 11-hydroxy-THC, the metabolite formed during first-pass liver conversion. A gummy taken at 10 p.m. is a different pharmacological situation at 7 a.m. than a joint smoked at the same hour.

Warning: Persistent vomiting after surgery in a heavy chronic user is not always the anesthetic. Cannabinoid hyperemesis syndrome gets misread as ordinary postoperative nausea and fails to respond to standard antiemetics (Atkins JB, et al., Cureus, 2025). If hot showers have ever relieved your nausea at home, mention it – that detail is diagnostic.

Interactions That Never Make It Onto the Medication List

THC gets broken down mostly by CYP3A4 and CYP2C9. CBD moves through CYP2C19 and CYP3A4, and inhibits a few of them on the way.

The fallout is measurable. In a pediatric epilepsy study, CBD pushed the active clobazam metabolite up by roughly 500% (Geffrey AL, et al., Epilepsia, 2015). Warfarin patients can see INR climb through that same CYP2C9 inhibition, and warfarin has almost no room for error. Transplant patients on tacrolimus can watch levels wander. Then there’s plain additive sedation once cannabis lands on top of opioids, benzodiazepines or gabapentinoids inside the same 48 hours.

None of this is exotic. It only becomes dangerous when the cannabis is missing from the medication list.

How to Say It in Thirty Seconds

Your team wants five specifics: what cannabinoid, what product form, how many milligrams, how frequently, and when you last used it.

“25 mg THC gummy, four or five nights a week, last one Tuesday evening” is a complete answer. “I smoke a little” is not.

On the fear that keeps people quiet – the ASA’s patient guidance states that anesthesiologists use the information solely to plan your surgery and recovery, share it only with team members who need it, and will not judge your behaviour. ASRA recommends against universal toxicology screening. Surgery gets postponed for acute intoxication or impaired decision-making capacity, not for an honest history.

The data suggest the silence is common. A 2024 study found roughly a quarter of patients weren’t consistently telling providers about cannabis at all, and the clinician was the one to raise it just 15.1% of the time (King DD, et al., Harm Reduction Journal, 2024). Stigma did most of the work.

What This Actually Buys You

The evidence base here is thinner than anyone would like – mostly observational, often single-centre, with genuine disagreement between studies on how much anesthetic a cannabis user really needs. No Indian perioperative cannabis guideline exists at all, and the pediatric literature is sparse.

What is not in dispute is the direction of the asymmetry. Disclosure costs you an awkward thirty seconds and gets you a tailored anesthetic plan, earlier multimodal pain control, and a team that recognises hyperemesis when it appears. Non-disclosure saves the awkwardness and hands your anesthesiologist an incomplete picture during the one procedure where being surprised is worst for everyone.

The question on that form is not a moral test. It is a dosing question wearing a moral disguise, and the people asking it have already heard every possible answer.

Stay updated, free articles. Join our Telegram channel

Join